What is DayTwo?
DayTwo provides personalized nutrition plans and actionable insights designed to help individuals maintain target blood glucose levels and live healthier lives. The company's unique approach is rooted in a comprehensive study of individual biometrics and lifestyle factors. The foundational research for DayTwo's program was conducted over five years by esteemed researchers Prof. Eran Segal and Prof. Eran Elinav at the Weizmann Institute of Science in Israel. The technology developed from this research was subsequently licensed to DayTwo, which was founded in 2015 to commercialize these findings. The company operates within the burgeoning health-tech and personalized medicine markets, leveraging scientific research to offer tangible health benefits.
How much funding has DayTwo raised?
DayTwo has raised a total of $85.4M across 6 funding rounds:
Series A
$12M
Series B
$31M
Other Financing Round
$5M
Debt
$150K
Debt
$254K
Unspecified
$37M
Series A (2017): $12M with participation from Johnson & Johnson and Seventure Partners
Series B (2019): $31M led by Seventure Partners, aMoon, Johnson & Johnson, and Ofek Ventures
Other Financing Round (2019): $5M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $254K backed by PPP
Unspecified (2021): $37M with participation from La’maison Fund, Micron Ventures, and Poalim Capital Markets
Key Investors in DayTwo
Johnson & Johnson
Johnson & Johnson is a global leader in healthcare, involved in the manufacturing of a wide range of consumer health, pharmaceutical, and medical device products. Their investment in DayTwo suggests a strategic interest in personalized health and chronic disease management solutions.
Seventure Partners
Seventure Partners is a venture capital firm that actively supports innovative companies in digital technologies and life sciences, including health and nutrition. Their investment aligns with their focus on pioneering health solutions and sustainable initiatives.
aMoon
aMoon is a venture capital fund focused on investing in the life sciences and healthcare sectors. Their backing of DayTwo indicates a commitment to advancing innovative technologies that improve patient outcomes and health management.
What's next for DayTwo?
The recent major strategic investment positions DayTwo for accelerated expansion and innovation. With a strong scientific foundation and a clear market need for personalized health solutions, the company is poised to enhance its service offerings and broaden its reach. Future developments are likely to focus on refining its biometric analysis, expanding its digital platform, and forging strategic partnerships to integrate its insights into broader healthcare ecosystems. This infusion of capital will be critical in navigating the competitive landscape and solidifying DayTwo's position as a leader in data-driven health management.
See full DayTwo company page
